[HTML][HTML] Strategies to improve antimicrobial utilization with a special focus on developing countries
Antimicrobial resistance (AMR) is a high priority across countries as it increases morbidity,
mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally …
mortality and costs. Concerns with AMR have resulted in multiple initiatives internationally …
[HTML][HTML] Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future
OO Ogunleye, D Basu, D Mueller, J Sneddon… - Frontiers in …, 2020 - frontiersin.org
Background The COVID-19 pandemic has already claimed considerable lives. There are
major concerns in Africa due to existing high prevalence rates for both infectious and non …
major concerns in Africa due to existing high prevalence rates for both infectious and non …
[HTML][HTML] Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across Africa and the implications for the future
Background There has been an appreciable increase in the number of people in Africa with
metabolic syndrome and Type 2 diabetes (T2DM) in recent years as a result of a number of …
metabolic syndrome and Type 2 diabetes (T2DM) in recent years as a result of a number of …
Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle …
Introduction: Antibiotics are indispensable to maintaining human health; however, their
overuse has resulted in resistant organisms, increasing morbidity, mortality and costs …
overuse has resulted in resistant organisms, increasing morbidity, mortality and costs …
[HTML][HTML] Barriers for access to new medicines: searching for the balance between rising costs and limited budgets
B Godman, A Bucsics, P Vella Bonanno… - Frontiers in Public …, 2018 - frontiersin.org
Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …
especially for cancer, immunological diseases, and orphan diseases. However, there are …
[HTML][HTML] The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …
However, in some countries, such as Netherlands, high discounts reported for the originator …
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications
J Charan, RJ Kaur, P Bhardwaj, M Haque… - Expert review of …, 2021 - Taylor & Francis
Objectives: Remdesivir has shown promise in the management of patients with COVID-19
although recent studies have shown concerns with its effectiveness in practice. Despite this …
although recent studies have shown concerns with its effectiveness in practice. Despite this …
Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries
Introduction There are positive aspects regarding the prescribing of fixed dose combinations
(FDCs) versus prescribing the medicines separately. However, these have to be balanced …
(FDCs) versus prescribing the medicines separately. However, these have to be balanced …
[HTML][HTML] Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: an epidemiological meta-analysis
NN Shen, C Zhang, Y Hang, Z Li, LC Kong… - Frontiers in …, 2021 - frontiersin.org
Background: The use of direct oral anticoagulant (DOAC) off-label doses in atrial fibrillation
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
B Godman, RE Malmström, E Diogene… - Expert review of …, 2015 - Taylor & Francis
Medicines have made an appreciable contribution to improving health. However, even high-
income countries are struggling to fund new premium-priced medicines. This will grow …
income countries are struggling to fund new premium-priced medicines. This will grow …